Cargando…

Natural Variation in Immune Responses to Neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian Infants

BACKGROUND: There is a need for new vaccines for tuberculosis (TB) that protect against adult pulmonary disease in regions where BCG is not effective. However, BCG could remain integral to TB control programmes because neonatal BCG protects against disseminated forms of childhood TB and many new vac...

Descripción completa

Detalles Bibliográficos
Autores principales: Finan, Chris, Ota, Martin O. C., Marchant, Arnaud, Newport, Melanie J.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567029/
https://www.ncbi.nlm.nih.gov/pubmed/18941532
http://dx.doi.org/10.1371/journal.pone.0003485
_version_ 1782159980597608448
author Finan, Chris
Ota, Martin O. C.
Marchant, Arnaud
Newport, Melanie J.
author_facet Finan, Chris
Ota, Martin O. C.
Marchant, Arnaud
Newport, Melanie J.
author_sort Finan, Chris
collection PubMed
description BACKGROUND: There is a need for new vaccines for tuberculosis (TB) that protect against adult pulmonary disease in regions where BCG is not effective. However, BCG could remain integral to TB control programmes because neonatal BCG protects against disseminated forms of childhood TB and many new vaccines rely on BCG to prime immunity or are recombinant strains of BCG. Interferon-gamma (IFN-γ) is required for immunity to mycobacteria and used as a marker of immunity when new vaccines are tested. Although BCG is widely given to neonates IFN-γ responses to BCG in this age group are poorly described. Characterisation of IFN-γ responses to BCG is required for interpretation of vaccine immunogenicity study data where BCG is part of the vaccination strategy. METHODOLOGY/PRINCIPAL FINDINGS: 236 healthy Gambian babies were vaccinated with M. bovis BCG at birth. IFN-γ, interleukin (IL)-5 and IL-13 responses to purified protein derivative (PPD), killed Mycobacterium tuberculosis (KMTB), M. tuberculosis short term culture filtrate (STCF) and M. bovis BCG antigen 85 complex (Ag85) were measured in a whole blood assay two months after vaccination. Cytokine responses varied up to 10 log-fold within this population. The majority of infants (89–98% depending on the antigen) made IFN-γ responses and there was significant correlation between IFN-γ responses to the different mycobacterial antigens (Spearman's coefficient ranged from 0.340 to 0.675, p = 10(−6)–10(−22)). IL-13 and IL-5 responses were generally low and there were more non-responders (33–75%) for these cytokines. Nonetheless, significant correlations were observed for IL-13 and IL-5 responses to different mycobacterial antigens CONCLUSIONS/SIGNIFICANCE: Cytokine responses to mycobacterial antigens in BCG-vaccinated infants are heterogeneous and there is significant inter-individual variation. Further studies in large populations of infants are required to identify the factors that determine variation in IFN-γ responses.
format Text
id pubmed-2567029
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-25670292008-10-22 Natural Variation in Immune Responses to Neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian Infants Finan, Chris Ota, Martin O. C. Marchant, Arnaud Newport, Melanie J. PLoS One Research Article BACKGROUND: There is a need for new vaccines for tuberculosis (TB) that protect against adult pulmonary disease in regions where BCG is not effective. However, BCG could remain integral to TB control programmes because neonatal BCG protects against disseminated forms of childhood TB and many new vaccines rely on BCG to prime immunity or are recombinant strains of BCG. Interferon-gamma (IFN-γ) is required for immunity to mycobacteria and used as a marker of immunity when new vaccines are tested. Although BCG is widely given to neonates IFN-γ responses to BCG in this age group are poorly described. Characterisation of IFN-γ responses to BCG is required for interpretation of vaccine immunogenicity study data where BCG is part of the vaccination strategy. METHODOLOGY/PRINCIPAL FINDINGS: 236 healthy Gambian babies were vaccinated with M. bovis BCG at birth. IFN-γ, interleukin (IL)-5 and IL-13 responses to purified protein derivative (PPD), killed Mycobacterium tuberculosis (KMTB), M. tuberculosis short term culture filtrate (STCF) and M. bovis BCG antigen 85 complex (Ag85) were measured in a whole blood assay two months after vaccination. Cytokine responses varied up to 10 log-fold within this population. The majority of infants (89–98% depending on the antigen) made IFN-γ responses and there was significant correlation between IFN-γ responses to the different mycobacterial antigens (Spearman's coefficient ranged from 0.340 to 0.675, p = 10(−6)–10(−22)). IL-13 and IL-5 responses were generally low and there were more non-responders (33–75%) for these cytokines. Nonetheless, significant correlations were observed for IL-13 and IL-5 responses to different mycobacterial antigens CONCLUSIONS/SIGNIFICANCE: Cytokine responses to mycobacterial antigens in BCG-vaccinated infants are heterogeneous and there is significant inter-individual variation. Further studies in large populations of infants are required to identify the factors that determine variation in IFN-γ responses. Public Library of Science 2008-10-22 /pmc/articles/PMC2567029/ /pubmed/18941532 http://dx.doi.org/10.1371/journal.pone.0003485 Text en Finan et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Finan, Chris
Ota, Martin O. C.
Marchant, Arnaud
Newport, Melanie J.
Natural Variation in Immune Responses to Neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian Infants
title Natural Variation in Immune Responses to Neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian Infants
title_full Natural Variation in Immune Responses to Neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian Infants
title_fullStr Natural Variation in Immune Responses to Neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian Infants
title_full_unstemmed Natural Variation in Immune Responses to Neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian Infants
title_short Natural Variation in Immune Responses to Neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian Infants
title_sort natural variation in immune responses to neonatal mycobacterium bovis bacillus calmette-guerin (bcg) vaccination in a cohort of gambian infants
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567029/
https://www.ncbi.nlm.nih.gov/pubmed/18941532
http://dx.doi.org/10.1371/journal.pone.0003485
work_keys_str_mv AT financhris naturalvariationinimmuneresponsestoneonatalmycobacteriumbovisbacilluscalmetteguerinbcgvaccinationinacohortofgambianinfants
AT otamartinoc naturalvariationinimmuneresponsestoneonatalmycobacteriumbovisbacilluscalmetteguerinbcgvaccinationinacohortofgambianinfants
AT marchantarnaud naturalvariationinimmuneresponsestoneonatalmycobacteriumbovisbacilluscalmetteguerinbcgvaccinationinacohortofgambianinfants
AT newportmelaniej naturalvariationinimmuneresponsestoneonatalmycobacteriumbovisbacilluscalmetteguerinbcgvaccinationinacohortofgambianinfants